Since the observation that dihydrofolic reductase is powerfully inhibited by the folic acid antagonists aminopterin 1 and amethopterin 2 (6) (7) (8) (9) (10) , the development of resistance to these agents has been studied in bacteria (11) (12) (13) (14) , cultured cells (15, 16), L-1210 leukemic mice (17) , and human leukemia (1, 18, 19) . In each of these instances, exposure of the system to the folic acid antagonists resulted in an increased level of dihydrofolic reductase, suggesting that these events were associated with resistance.
In a previous study (19) , an increased level of dihydrofolic reductase after amethopterin was noted in the leukocytes from patients with leukemia. The present investigation extends these observations and includes the effect of amethopterin treatment on the level of dihydrofolic reductase in leukocytes and erythrocytes of nonleukemic patients. A possible mechanism is proposed to account for the increased enzyme level in normal and leukemic cells exposed to amethopterin.
MATERIALS AND METHODS
Chemicals. ATP,3 TPN,3 TPNH,3 DPN,' DPNH, 3 folic acid,4 and protamine sulfate 4 were obtained from manufacturers. DEAE-cellulose5 was prepared according to the method of Sober, Gotter, Wyckoff, and Peterson (20) . Dihydrofolic acid was prepared according to the procedure of Futterman (21) as modified by Blakley (22) .
Methods. Venous blood was collected in heparin from patients at the King County Hospital or the Clinical Research Center of the University of Washington Hospital. Leukocytes were isolated from blood and lysed by high speed homogenization by procedures described elsewhere (23 Enzyme assays. Formate-activating enzyme was assayed in leukocytes and erythrocytes by methods described previously (23, 24) . Dihydrofolic reductase was assayed by an indirect method in which the tetrahydrofolate formed in reaction 1 was measured with excess formate-activating enzyme (10) . A direct assay, which measures the disappearance of both TPNH and dihydrofolate by the decrease in absorbancy at 340 mu, was used with more purified enzyme preparations (17, 25) .
Measurement of amethopterin. Intracellular amethopterin, bound to leukocyte or erythrocyte protein, was measured by its ability to inhibit a purified dihydrofolic reductase from guinea pig liver (26 (27) (28) . The dialyzed solution was then added to 0.5 vol of a DEAEcellulose suspension (80 mg per ml), the mixture was stirred for 10 minutes at 40 C, centrifuged at 900 g for 10 minutes, and the unabsorbed fraction was discarded. The DEAE-cellulose was washed with three 20-ml portions of 0.5 M KCl, and the resultant eluant fractions were combined and Iyophilized to dryness (29 terin treatment, studies were carried out on nonleukemic subjects. Table I gives information regarding the diagnosis, treatment of each patient, and "peak" dihydrofolic reductase activities. Initially, three patients comprising group 1 of Table  I were studied before and after treatment with daily doses of amethopterin. Reductase activity was not detected in either the leukocytes or erythrocytes of any patient before therapy, but after amethopterin, enzyme activity appeared in both types of cells. Detailed data on the rate of appearance and level of this enzyme as well as similar data for the formate-activating enzyme in one of these patients, V.M., are presented in Figure  2 , A and B. Dihydrofolic reductase activity was first detected in the leukocytes and erythrocytes of this patient 5 days after amethopterin treatment was initiated, and higher levels of the enzyme were found 8 and 15 days after the start of therapy. Treatment with amethopterin was discontinued on day 15, and thereafter the level of the leukocyte enzyme decreased rapidly, while a slower decline was noted for the erythrocyte enzyme. The increase in erythrocyte formate-activating enzyme seen in Figure 2 has been shown previously to be associated with reticulocytosis (24). In group 2 of Figure 5 . As in other patients with untreated chronic myelocytic leukemia, a measurable level of leukocyte dihydrofolic reductase was present before amethopterin. After a single dose, the activity increased .rapidly and after 7 days reached a peak value more than 10 times greater than the pretreatment level. The amount of amethopterin present in the leukocytes was determined (see Figure 5) . The appearance and subsequent rise of intracellular inhibitor closely paralleled the rise in dihydrofolic reductase activity. As in the preceding patient, the leukocyte count and differential count in this patient remained relatively constant after amethopterin.
Reactivation of inhibited leukocyte dihydrofolic reductase. Since it has been shown above that amethopterin is present in the leukocytes of the chronic myelocytic leukemia patient N.M. after treatment, it was of interest to attempt the reactivation of any enzyme in the inhibited state. On day 10 after amethopterin, leukocytes were isolated from 100 ml of this patient's blood, and the lysate from these cells was treated according to the chromatographic procedure for the purification of dihydrofolic reductase. As shown in Table III , dialysis did not dissociate the enzyme-inhibitor complex. After chromatography, however, all of the enzyme activity was found in the 0.15 M KCl fraction. The data in Table III show that the total units of enzyme activity had almost doubled after the chromatographic step, indicating that a considerable amount of inhibited enzyme had been reactivated.
Number of molecules of amethopterin per leutkocyte and total amethopterin content of the circulating leukocytes. In the preceding experiment, the data on the number of leukocytes, the milligrams of soluble protein per leukocyte, and the amethopterin content of the extract can be used to calculate the amount of amethopterin present in each leukocyte. Since the amount of amethopterin found per milligram of cellular protein on day 7 was 8 x 10-6 jumoles and 50 mg of protein was released per 109 leukocytes lysed, the amount of amethopterin per cell is approximately 4 x 10-19 moles. This calculation assumes that the inhibitor is distributed uniformly among the various cells at the time of analysis, i.e., on day 7 after amethopterin. If the 100 ml of blood, from which 4 x 109 leukocytes were obtained, is assumed to represent 2% of the total circulating leukocytes, then the total amount of amethopterin present in all of the circulating leukocytes on this day would be 0.08 umole, or approximately 0.04 
DISCUSSION
The key role of the folic acid coenzyme tetrahydrofolate in the synthesis of inosinate, thymidylate, histidine, and methionine is now well established (4, (30) (31) (32) . Inhibition of dihydrofolic reductase by amethopterin prevents the synthesis of tetrahydrofolate, thereby interfering with each of the biosynthetic reactions above.
The rise in dihydrofolic reductase activity observed in bacteria and mouse leukemia cells after exposure to antifolic agents has been attributed to the selective survival of those cells having a higher initial level of enzyme (11) (12) (13) (14) (15) (16) (17) . Several findings in the present study indicate that the mechanism for increased dihydrofolic reductase in leukocytes and erythrocytes of patients after amethopterin treatment is not cell selection, but that enzyme "induction" S actually occurs. The first of these findings is that a single, relatively nontoxic dose of amethopterin results in the rise of dihydrofolic reductase, and the prolonged administration of an agent usually essential for the selection of resistant cell population is not necessary. Second, the time course of the rise in dihydrofolic reductase level is more in keeping with enzyme induction than with cell selection. Thus, the enzyme level rises to a peak from 9 to 14 days after amethopterin and then declines, in contrast with the prolonged plateau of high activity found in the other systems when amethopterin administration is stopped. The time sequence of the rise and fall of the enzyme activity in the leukocytes of nonleukemic patients bears a great resemblance to the curves describing granulocyte life-span obtained with tritiated thymidine. p32, and DFP32 (diisopropylfluorophosphate) (33) (34) (35) (36) . Likewise, in the single subject with chronic lymphocytic leukemia who was investigated, the slower decline of amethopterin-induced dihydrofolic reductase activity parallels the longer life-span reported for mature lymphocytes. Similarly, the curve of erythrocyte dihydrofolic reductase induced by amethopterin closely approximates the 8 Enzyme "induction" is used here to mean an increase in dihydrofolic reductase activity in response to the stimulus of amethopterin.
erythrocyte-labeling curve obtained after the administration in zivo of Fe59 (37 The strongest evidence in favor of enzyme induction is perhaps the demonstration that the presence, rise, and fall of the inhibitor in the leukocyte closely parallels the level of the enzyme ( Figure 5 ). This is in keeping with the concept (38) that the presence of inducer in the cell is essential for enzyme induction.
In light of the present findings, the following mechanism is tentatively proposed to explain the rise observed in dihydrofolic reductase activity in leukocytes and erythrocytes after amethopterin treatment. Amethopterin is taken up by dividing cells in the bone marrow and to some degree inhibits the existing intracellular dihydrofolic reductase. In these cells that do not take up lethal amounts of amethopterin, the partial metabolic block results in a reduced amount of tetrahydrofolate. which in turn causes a reduction in the synthesis of some key metabolite (e.g., a pyrimidine, purine, or amino acid) necessary for further cell division. If this metabolite acts, moreover, as a repressor in the synthesis of dihydrofolic reductase. a decreased amount of the metabolite would cause an increased synthesis of the enzyme. Thus, the net effect of this chain of events would be to overcome the original amethopterin block, and the resulting increased level of reductase would then persist during the life span of each cell. The properties of such an induced enzyme should be similar in all respects to those of the original enzyme (19) , as the present study shows is the case. A somewhat analogous mechanism has been postulated to explain the inhibition of histidine synthesis that occurs when bacteria are treated with the histidine analogue thiazolealanine (39) . An alternative explanation for the observed rise is also possible, i.e., this is enzyme induction in the sense that the amethopterin acts as a substrate for dihydrofolic reductase (folic acid or dihydrofolic acid) and not by a derepression mechanism. This interpretation is less appealing, since folic acid administration did not result in increased enzyme activitv, but inasmuch as analogues can be better enzyme inducers than substrates, this possibility cannot be discounted. sistance has not yet been assessed adequately in human leukemia and may prove to be an additional factor. A better understanding of possible control mechanisms involved in the biosynthesis of the protein dihydrofolic reductase and the manner of transport in the body of the folic acid antagonists might result in a more effective regimen for selection and treatment of leukemia patients with the currently used antifolic agents.
SUMMARY
After administration of amethopterin, the appearance of measurable levels of dihydrofolic reductase has been observed in the leukocytes of seven patients with nonhematologic diseases. In five patients (three with nonhematologic neoplasms, one with chronic myelocytic leukemia, and one with chronic lymphocytic leukemia), a single 20-mg infusion of amethopterin was given. In all instances, dihydrofolic reductase activity appeared in the leukocytes and erythrocytes within 1 week. In the subject with chronic myelocytic leukemia, a tenfold rise over the pretreatment value occurred in the level of the enzyme.
Studies of the induced enzyme from the leukocytes of the nonhematologic patients showed that the kinetic properties, including inhibition by amethopterin, were similar to those reported previously for the enzyme isolated from leukemic leukocytes. In leukocytes from a patient with chronic myelocytic leukemia treated with amethopterin, the accumulation of inhibitor paralleled the increase in dihydrofolic reductase activity. These observations suggest that the mechanism of reductase inhibition involves the uptake of amethopterin by immature cells, inhibition of dihydrofolic reductase activity, and a resultant decrease in the formation of tetrahydrofolate. This sequence could lead to a decreased synthesis of some metabolite that ordinarily represses the synthesis of dihydrofolic reductase. Thus, the enzyme level ultimately rises and remains elevated during the life-span of the cell.
